Combined treatment for BRVO reduces re-injection need

Article

Patients who have macular oedema secondary to branch retinal vein occlusion (BRVO) see improved anatomic and functional outcomes with combined intravitreal bevacizumab (IVB) and intravitreal triamcinolone acetate (IVT) therapy when it is delivered early in the disease process, according to the findings of recently published research.

Patients who have macular oedema secondary to branch retinal vein occlusion (BRVO) see improved anatomic and functional outcomes with combined intravitreal bevacizumab (IVB) and intravitreal triamcinolone acetate (IVT) therapy when it is delivered early in the disease process, according to the findings of research published in the Indian Journal of Ophthalmology.

"An important benefit from the presented treatment protocol is the decreased need for multiple re-injections when compared to other studies describing the standard of care," write the Galveston, Texas, researchers.

In their study, the investigators retrospectively analysed 20 eyes that had been injected with 1.25 mg IVB and 2 mg IVT within 8 weeks of onset of clinically identified BRVO. No patient had concomitant ocular pathology, and all underwent 6 months of follow-up. The researchers used spectral-domain optical coherence tomography (OCT; Spectralis, Heidelberg Engineering) to examine eyes for LogMAR visual acuity (VA) and central macular thickness (CMT) preoperatively and 1, 3 and 6 months postoperatively.

The patients had a mean age of 61.3 years and a mean BRVO diagnosis time of 3 weeks at presentation. Their VA improved from logMAR 1.08 preoperatively to mean logMAR VA of 0.55 ± 0.17 at 1 month, 0.56 ± 0.21 at 3 months, and 0.38 ± 0.1 at 6 months. Their mean CMT improved from 482 ± 107 μm preoperatively to 319 ± 53 μm at 1 month, 344 ± 89 μm at 3 months, and 241 ± 29 μm at 6 months. Their mean IOP preoperatively was 16.5 mmHg, 21 mmHg at 1 month, and 15 mmHg at 6 months. At 3 months, 6 out of 20 patients had re-injections of IVB and IVT.

"The prolonged anti-vascular endothelial growth factor effect of combined IVB and IVT may be helpful in reducing the number of intravitreal injections required to achieve prompt and sustained decrease in macular oedema. It may also help to reduce the risk of elevated IOP associated with corticosteroids if fewer injections are administered," the researchers write. "IVB and IVT may be a particularly good option when argon laser photocoagulation cannot be administered. IVB and IVT may have a synergistic effect on minimizing the sequelae of vision threatening macular oedema secondary to BRVO, but further randomized clinical trials with control groups are needed."

To read the study, visit the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.